Indian pharma heirs wager large sums on the next costly drug wave

·1 views

Members of India's pharmaceutical founding families are committing substantial capital to a new round of expensive development projects. The bets reflect a broader industry push toward costlier, more complex therapies that could reshape the sector's growth. The report frames these investments as a significant generational test for family-run drugmakers. Specific figures and timelines are not included in the provided text.

Read the full story at Economic Times

This is an AI-generated summary. ShortSingh links to the original source for the complete article.

Discussion (0)

Indian Americans hit back after Seattle Diwali event

0 comments Read more at Economic Times

BusinessEconomic Times ·

Adani Group plans ₹35,000–40,000 crore in annual capital expenditure

The Adani Group has outlined plans to invest between ₹35,000 and ₹40,000 crore in capital expenditure each year. The figure reflects the conglomerate's ongoing push to expand its infrastructure and business portfolio. Such spending typically funds new projects, asset build-out, and capacity growth across the group's operations. The article provides no further breakdown of sectors or timelines beyond the annual range. Readers should note the figures are forward-looking plans rather than completed investments.

0 comments Read more at Economic Times

BusinessEconomic Times ·

Modi heads to Bastar for Diwali with security forces

0 comments Read more at Economic Times

BusinessEconomic Times ·

Small parties make big gains across New Zealand

0 comments Read more at Economic Times